Study of ARO-APOC3 in Adults With Dyslipidemia
← catalyst calendarSponsored by Arrowhead Pharmaceuticals (industry) · ARWR — their whole pipeline →.
Phase
Phase 2
Status
Completed
Study type
Interventional
Design
Na · None · Treatment
Enrollment
418actual
Sites
60
Countries
Australia, Canada, Hungary +4
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-07-07 | actual | When the study began enrolling |
| Primary completion | 2025-09-22 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-09-22 | actual | The whole study's end, after follow-up |
| First posted | 2022-06-09 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-12 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Dyslipidemias
Intervention
- Drug: ARO-APOC3
Primary outcome
what the primary-completion date above is the date OFNumber of Participants with Treatment-Emergent Adverse Events (TEAEs)
measured Through 24 months
Publications
- PMID 42291067 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · ARWR's whole pipeline · Catalyst calendar · Every registered study · What changed